Botswana vs Cuba: Number of clinical trials

Botswana
1 trials
in 2024
Cuba
1 trials
in 2024
Botswana rank
127th
Cuba rank
127th

Number of clinical trials over time

  • Botswana
  • Cuba
0246810200520142024

How they compare

Botswana currently reports 1 trials against 1 trials in Cuba, a difference of 0 trials.

The two have swapped places 6 times across 14 shared years of data; in 2007 it was Cuba ahead.

Botswana ranks 127th and Cuba ranks 127th of 153 countries.

Across the 3 decades both report, Botswana averaged higher in 1 and Cuba in 2.

Head to head by decade

Decade Botswana Cuba Difference Ahead
2000s 1 trials 3 trials 2 trials Cuba
2010s 2.88 trials 4 trials 1.12 trials Cuba
2020s 3.25 trials 1.25 trials 2 trials Botswana

Averages of every year both report within each decade.

Frequently asked questions

Which has higher number of clinical trials, Botswana or Cuba?
Botswana, at 1 trials against 1 trials in Cuba as of 2024.
What is the difference in number of clinical trials between Botswana and Cuba?
0 trials, with Botswana ahead.
How many years of comparable data are there for Botswana and Cuba?
14 years are reported by both, from 2007 to 2024.
How do Botswana and Cuba rank globally for number of clinical trials?
Botswana ranks 127th and Cuba ranks 127th of 153 countries.
Where does this data come from?
ClinicalTrials.gov (2025) – with major processing by Our World in Data, published as Number of clinical trials. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Number of clinical trials
Unit
trials
Source
ClinicalTrials.gov (2025) – with major processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
153 places, 2,621 data points, 2000–2024
Last refreshed

Annual number of completed clinical trials registered in the ClinicalTrials.gov database for each country. Registration in the ClinicalTrials database is mandatory for trials in the United States, but voluntary for other countries.